Table 5.
One-way sensitivity analysis
| Base case | Sensitivity | Cost (£) |
QALY |
ICER | Change in ICER (%) | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Parameter | Comparator | Intervention | Difference | Comparator | Intervention | Difference | ||||
| Base case | – | – | 7460.21 | 8469.79 | 1009.58 | 1.35 | 1.59 | 0.24 | 4251.60 | – |
| Utility | Brown et al TTO | Brown et al SG | 7460.21 | 8469.79 | 1009.58 | 1.54 | 1.73 | 0.19 | 5126.51 | +21 |
| Cost | Drug and visit | Drug only | 6232.08 | 7110.14 | 878.06 | 1.35 | 1.59 | 0.24 | 3697.82 | –13 |
| Time horizon | 2 years | 5 years | 15 000.16 | 15 998.43 | 998.27 | 3.01 | 3.57 | 0.56 | 1773.21 | –58 |
| Starting age | 78.8* | 60† | 7771.01 | 8768.44 | 997.43 | 1.42 | 1.67 | 0.25 | 3909.36 | –8 |
Source: Brown et al.9
*Distribution defined by characteristics of data set.
†Fixed starting age for cohort.
ICER, incremental cost-effectiveness ratio; SG, standard gamble; TTO, time trade-off; QALY, quality-adjusted life year.